Infection of hepatitis B virus (HBV) occurs in ~10% of infants of HBV-infected mothers with positive hepatitis B e antigen (HBeAg) after immunoprophylaxis. We aimed to evaluate the safety and efficacy of telbivudine used during late pregnancy for preventing mother-to-child transmission of HBV. We conducted a multicenter prospective cohort study in 5 hospitals from 2012 to 2014, which enrolled HBV-infected singleton pregnant women with positive HBeAg. By their choice, women were divided into therapy (telbivudine 600 mg/day, from gestation 28-32 weeks to 3-4 weeks postpartum) and control (no antiviral agent) groups. Infants received passive-active immunoprophylaxis and follow-up at the age of 7-14 months. Totally, 328 pregnant women were included: 149 in the telbivudine group and 179 in the control group. Baseline HBV DNA levels were similar in the 2 groups (7.43 vs 7.37 log 10 IU/mL, P = .711). At delivery, HBV DNA levels in the telbivudine and control groups were 3.80 and 7.26 log 10 IU/ mL, respectively (P < .0001). Of the infants, 128 (85.9%) in the telbivudine group and 156 (87.2%) in the control group were followed up. No infant in the telbivudine group had chronic infection, while 2 (1.28%) infants in the control group did (P = .503). Three (2.34%) infants in the telbivudine group, but none in the control group, had severe congenital or developmental abnormalities (P = .090). The data indicate that Abbreviations: ALT, alanine aminotransferase; Anti-HBc, antibody against hepatitis B core antigen; HBeAg, hepatitis B e antigen; HBIG, hepatitis B immunoglobulin; HBsAg, hepatitis B surface; HIV, hepatitis B virus; MTCT, Mother-to-child transmission; RT, reverse transcriptase.
| PATIENTS AND METHODS

| Study population and design
This was a multicenter prospective cohort study to evaluate the safety and efficacy of telbivudine used in the third trimester of pregnant women in preventing MTCT of HBV, conducted between April 2012 and October 2014. Pregnant women with positive hepatitis B surface (HBsAg) and HBeAg attending the 5 participating hospitals in China were invited to participate in this study after detailed explanation and assigned into the telbivudine or control group based on the pregnant women's choice. The women in the telbivudine group took telbivudine (600 mg/day), from 28-32 weeks of gestation to 3-4 weeks postpartum, while those in the control group were not treated with any antiviral agents. All women received routine prenatal examinations. Women were excluded when they met any of following criteria: (i) twin pregnancy, (ii) co-infection with hepatitis A, C and E, HIV or syphilis, (iii) anti-HBV treatment history more than 6 months, (iv) severe chronic disease, including heart and kidney diseases, asthma, liver cirrhosis, diabetes, hyperthyroidism, epilepsy and any mental disorders, severe haematologic diseases and autoimmune disease, (v) threatened miscarriage or relevant treatment during pregnancy, (vi) severe pregnancy complications, including preeclampsia and intrauterine foetal growth restriction, (vii) history of foetal deformity, or foetal deformity detected by ultrasound examination in the current pregnancy and (viii) alanine aminotransferase (ALT) >10 times upper limit, or total bilirubin >3 times upper limit, of normal value. All eligible women provided informed consent and consented to follow-up of their children. The study was approved by the institutional ethics review committee in each hospital and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The study has been registered in ClinicalTrials.gov (no. NCT01637844).
| Recommended combined immunoprophylaxis in infants
All neonates were intramuscularly injected with HBIG (100 IU) and recombinant yeast hepatitis B vaccine (10 μg) as soon as possible after birth, preferably <24 hours after birth. The infants were administered 2 additional doses of the vaccine at 1 and 6 months old, respectively.
| Collection of pregnancy, delivery and neonatal outcomes
All data about the pregnancy, delivery and neonatal outcomes were prospectively collected and recorded by the obstetricians in each participating hospital. Safety parameters for the pregnant women included the levels of ALT, serum creatinine and creatinine kinase, symptoms and signs of any adverse events, oligohydramnios or polyhydramnios estimated by ultrasound examination and postpartum haemorrhage. Infant safety parameters included rates of premature birth, Apgar scores, birth weight and length, any congenital malformations and developmental abnormalities during the follow-up, which covered a period from enrolment to 7-14 months after delivery. When an infant was suspected with congenital or developmental anomaly, the infant was further evaluated by the relevant specialists to ascertain the diagnosis.
| Sample size determination
The sample size was determined based on the estimation of perinatal infection rates in infants of HBV-infected mothers positive telbivudine may block perinatal HBV transmission. However, larger studies are required to clarify whether anti-HBV therapy in pregnancy is associated with severe adverse effects in the foetuses and infants.
K E Y W O R D S
antiviral therapy, hepatitis B, mother-to-child transmission, pregnant women for HBeAg. Under combined passive-active immunoprophylaxis, around 10% of the infants born to HBeAg-positive mothers would be infected with HBV. 8, 10 We assumed that the perinatal infection rate would be reduced to 1% after the mothers were treated with telbivudine. The calculated sample size was 87 in each group with an α of 0.05 and a power of 80%. Considering the expected loss to follow-up as ~15%, the minimum number of pregnant women recruited should be 87 × (1 + 15%) = 100 in each group. nih.gov/projects/genotyping/view.cgi?db=2). In addition, as the S gene is overlapped with the reverse transcriptase (RT) region of HBV, the drug resistance mutations in the telbivudine-treated pregnant women were also analysed by sequencing the RT region.
| Laboratory tests
| Primary efficacy endpoint
The primary efficacy endpoint of this study was the rate of ongoing HBV infection in infants at the age of 7-14 months, that is, the rate of MTCT of HBV. The ongoing infection was defined when an infant was positive for HBsAg and any 1 or more other HBV markers including HBeAg, anti-HBc and HBV DNA at the age of 7-14 months. We 
| Statistical analysis
| RESULTS
| Study subjects
During the study period between April 2012 and October 2014, a total of 328 singleton pregnant women with chronic HBV infection who met the inclusion criteria and signed informed consent were enrolled. Totally, 149 pregnant women were included in the telbivudine group and 179 in the control group ( Figure 1 ). Accordingly, 149 and 179 neonates were born to the telbivudine group and control group women, respectively. Of these subjects, 103 (69.1%) mothers and 128 (85.9%) infants in the telbivudine group and 124
(69.3%) mothers and 156 (87.2%) infants in the control group were followed up at 7-14 months postpartum, respectively ( Figure 1 ). As some mothers had to work in other cities and were not available for follow-up and these infants were brought to hospitals by their fathers or grandparents, more infants received follow-up evaluation than mothers.
| Baseline characteristics of pregnant women
The baseline demographics and laboratory characteristics of the pregnant women were mostly comparable in the 2 groups ( Table 1 ).
The average HBV DNA level in telbivudine group before taking the medication was similar to that in the control group (7.43 ± 1.26 vs 7.37 ± 1.49 log 10 IU/mL, t = 0.371, P = .711). There were no statistical differences in the proportion of high HBV DNA levels (≥2 × 10 7 IU/ mL) between the telbivudine and control groups (73.2% vs 74.9%, Table 1 ). Additionally, the levels of HBsAg and HBeAg were each comparable between the 2 groups (Table 1) .
| Tolerability and efficacy of telbivudine in pregnant women and postpartum
Of 149 pregnant women in the telbivudine group, 36 (24.2%) experienced 1 or more of the following adverse events: fatigue, headache and/or dizziness, mild myalgia and/or arthralgia, epigastric discomfort or pain, anorexia, nausea and vomiting, upper abdominal distention, and diarrhoea. The incidence was higher than that which occurred in the control group (24/179, 13.4%, χ 2 = 6.291, P = .012). Additionally, in the telbivudine group, 2 women with mild myalgia transiently experienced slight elevation of creatine kinase (228 and 246 U/L, reference value <171 U/L), while no woman had elevated serum creatinine levels. The adverse events were usually mild to moderate and were generally eased or disappeared after 2 weeks. Only 1 woman had serious dizziness after 1 week's telbivudine and had to keep lying in bed;
she was advised to stop telbivudine but she insisted on taking the medicine, and her dizziness gradually subsided after 17 days.
In the telbivudine group, the mean treatment duration prior to delivery was 68.2 ± 13.6 days. At delivery, HBV DNA levels were significantly reduced, with a mean reduction of 3.63 log 10 IU/mL, and 135 (90.6%) women had HBV DNA <2 × 10 5 log 10 IU/mL, while the levels of HBsAg and HBeAg had no remarkable changes (Table 2) .
Noticeably, at delivery, 7 (4.7%) of the 149 telbivudine-treated pregnant women still had high HBV DNA levels (≥2 × 10 7 IU/mL, Table 2) that were similar to the baseline levels, suggesting potentially primary drug resistance. As the RT region of HBV is overlapped with the S gene, we analysed the S gene sequence of each woman at baseline.
We paid particular attention to the RT sequence in these 7 women.
We also analysed the RT sequences in these 7 women at delivery. The results showed that the RT sequences before and after telbivudine treatment in the 7 women were all wild type, and no drug resistance mutation was observed. Thus, the inefficacy of telbivudine in these 7 women was less likely to be primary drug resistance. Whether the pregnancy may interfere with the pharmacokinetics and/or pharmacodynamics of telbivudine merits further study. Additionally, we did not find rebound of HBV DNA levels in any other pregnant women during the use of telbivudine. The proportion of women with ALT >40 U/L in the treated and control groups at delivery was 5.4% and 6.7%, respectively ( Table 2 ).
At 7-14 months postpartum, 103 and 124 mothers were followed up in the treated and untreated groups, respectively. All of them were still HBsAg positive; 9 (8.7%) and 10 (8.1%) women in the telbivudine and control groups lost HBeAg and seroconverted to anti-HBe, respectively (χ 2 = 0.033, P = .855), which are similar to the rates of postpartum spontaneous HBeAg seroconversion reported previously. 26, 27 The HBV DNA levels in the treated women rebounded nearly to baseline values (Table 2) . Additionally, the proportion of women with ALT >40 U/L in the 2 groups were comparable (21.4% vs 20.2%, χ 2 = 0.049, P = .825), mostly with mild elevation (<100 U/L, 72.7% and 84.0% respectively) and normalization within 2-4 weeks, which is similar to the 25% postpartum ALT flare reported from Australia. 28 No woman developed severe liver function deterioration (elevation of bilirubin) or fulminant hepatitis.
| Obstetric, neonatal and infant outcomes
The main obstetric outcomes in the telbivudine and control groups are listed in Table 3 . The main adverse obstetric outcomes, including oligohydramnios, polyhydramnios, premature labour, postpartum haemorrhage, showed no significant statistical differences. The gestational ages and Caesarean section rates were each similar in the 2 groups.
Neonatal growth parameters were comparable between the 2 groups (Table 3) . However, in the telbivudine group, 1 boy showed anotia (right) at birth; during follow-up, 2 other infants had development defects: a boy was diagnosed with cerebral palsy at the age of 6 months, and a girl was defined to have cinesipathy as she could not stand by herself even at 17 months old. Her mother experienced oligohydramnios during pregnancy. These 2 mothers delivered their neonates by Caesarean section, with 1 (cerebral palsy) due to social factors (Caesarean section without medical indications) at 37 +3 weeks of gestation and the other (cinesipathy) due to oligohydramnios at 38 weeks of gestation. By contrast, no remarkable congenital abnormalities were observed in infants at birth and during the follow-up in the control group.
| Immunoprophylaxis, infection with HBV and anti-HBs response in infants
Of 149 infants in the telbivudine group and 179 infants in the control group, 128 (85.9%) and 156 (87.2%) were followed up at 7-14 months old, respectively ( Figure 1 ). All neonates were administered HBIG within 24 hours (within 1 hour in 55.5% in the telbivudine group and 62.2% in the control group) after birth ( Table 4) . They also received the timely birth dose vaccine, except 2 in the telbivudine group and 1 in the control group who did not receive the first dose vaccine until 2-3 weeks old, respectively, because of their premature birth (Table 4) ; these 3 neonates received an additional HBIG dose at 3 weeks old. All infants received second and third dose hepatitis B vaccine according to the vaccination schedule.
Hepatitis B virus markers in the umbilical blood or peripheral blood samples collected within 24 hours after birth are presented in Table 4 . The detectable rate of HBV DNA in neonates of treated mothers was much lower than that in neonates of untreated mothers (14.8% vs 45.3%, χ 2 = 30.550, P < .0001), while positive rates of HBsAg and HBeAg were similar between the 2 groups. Additionally, all birth blood samples in both groups were negative for anti-HBc
IgM. (Table 4) . Table 4 also presents the anti-HBs responses in infants. Both groups had a very high proportion who were anti-HBs positive ≥10 mIU/mL (96.1% vs 97.4%, Fisher's exact, P = .736). In those uninfected infants with anti-HBs <10 mIU/mL, most of them still had detectable anti-HBs (2-9.9 mIU/mL), which may be considered to be immunity to HBV as previously reported.
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| DISCUSSION
The present study demonstrates that use of telbivudine in the third trimester of HBV-infected pregnant women with positive HBeAg may block MTCT of HBV. Impressively, we found that only 1.28%
of the infants born to the mothers without anti-HBV therapy during pregnancy had chronic HBV infection, indicating that very early use of HBIG and vaccine in neonates after birth, rather than within 24 hours, may further increase the protective efficacy of the current immunoprophylaxis.
Studies have shown that any of lamivudine, telbivudine or tenofovir may significantly reduce or completely block MTCT of HBV. [14] [15] [16] [17] [18] [19] [20] [21] [22] In the present study, although the difference of ongoing HBV infection rates in the treatment and control groups had no statistical significance (Table 4) , the main reason may be attributed to the very low infection rate (1.28%) in infants born to the untreated mothers. It is generally considered that ~7% of infants born to HBeAg-positive mothers may be chronically infected even after passive and active immunoprophylaxis. 30 As no chronic infection occurred in infants of treated mothers in the present study, we considered that telbivudine treatment in highly viremic mothers may reduce perinatal HBV transmission, compared with the infection rate documented in the literature. No chronic infection in infants born to telbivudine-treated mothers with high viral loads may be attributed to 2 reasons: substantial reduction of maternal viral loads at delivery (Table 2 ) and timely use of both HBIG and hepatitis B vaccine (Table 4 ).
In the present study, more women chose not to take telbivudine (Figure 1) , as reported by others. 15, 18 The main reason was that the women were worried about the side effects of drug exposure in pregnancy. Although some studies reported that telbivudine used in pregnancy had no any adverse events, 19, 20 we found that the common adverse events of telbivudine observed in hepatitis B patients, One boy showed anotia (right) at birth and still lacked the ear during the follow-up, and 2 other infants were diagnosed with cerebral palsy and cinesipathy, respectively.
frequently occurred in the treated pregnant women. Furthermore, we observed that 3 (2.3%) infants of telbivudine-treated mothers showed severe congenital or development abnormalities (Table 3) .
Even though pregnant women with many underlying diseases associated with congenital abnormalities were excluded (see Study Design), the incidence (2.3%) of congenital abnormalities in the present study is somewhat higher than the estimated 1.5% of birth defects in the general infant population in China. However, the overall incidence of congenital malformations in infants born to HBV-infected mothers is unknown. Therefore, based on the data of this study, it is difficult to establish or exclude the link between telbivudine and severe abnormalities at this moment.
The safety of in utero exposure to antiviral nucleoside/nucleotide analogues remains a concern. Although a meta-analysis shows that the use of telbivudine, lamivudine or tenofovir during pregnancy appears to be safe with no increased adverse maternal or foetal outcomes, 31 there are several problems in the most cited articles in this meta-analysis. 32 Virtually, many other investigators also reported congenital abnormalities in infants of mothers with anti-HBV therapy 16, 17, [33] [34] [35] or stillbirth or neonate death after use of antiviral agents in pregnant women. 15, 16, 22 One of the 3 severe abnormalities in our study was anotia, which also occurred in 1 of 43 infants of mothers treated with lamivudine. 16 Anotia is a structural abnormality and formation of ears in the foetus should be complete when the women were exposed to the drugs. However, as anotia is very rare, repeated occurrence in infants of mothers treated with anti-HBV agents cannot completely rule out the association; whether atrophic changes may occur in ears under some circumstances is unknown. Other ear abnormalities in infants of mothers treated with anti-HBV agents, such as ear accessories and hearing loss, were also reported. 16, 33 Additionally, repeated occurrence of cerebral palsy, 34 low birth weight 15, 33, 34 and polydactyly 16, 21 indicates that adverse events occurring in infants of anti-HBV-treated mothers are not rare. Moreover, the investigators who firstly reported no congenital abnormality in infants of mothers treated with telbivudine 14 found 1 congenital megacolon and another congenital patent ductus arteriosus in 214 children in the extended follow-up. 36 We summarized the adverse events in mothers and neonates/infants associated with oral anti-HBV treatment during pregnancy previously as documented in the English literature (see Table S1 ). Therefore, we consider that more studies with careful surveillance of severe adverse events in infants are required before anti-HBV therapy is routinely recommended in women with high viral loads to prevent MTCT of HBV. This is in agreement with the World Health Organization Anti-HBc, antibody against hepatitis B core antigen; Anti-HBs, antibody against HBsAg; HBeAg, hepatitis B e antigen; HBIG, hepatitis B immunoglobulin; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus. a Due to premature birth, 2 neonates in the treated group and one in the control group received the first dose vaccine at 2-3 wk old, respectively; they all received second dose of HBIG at 3 wk old. b All these infants had anti-HBs >10 mIU/mL and were negative for HBV DNA. c These 2 infants were positive for HBsAg and HBeAg, and HBV DNA.
viewpoint that potential harms of antiviral use in pregnancy need to be more fully evaluated.
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An unexpected and interesting finding in the present study is the very low rate (1.28%) of chronic HBV infection in infants of the mothers without antiviral therapy, which is much lower than the reported rate of ~10%. 8, 10 We considered that it may be attributed to the immediate use of HBIG and the vaccine in neonates after birth, as most of the infants received combined immunoprophylaxis within 1 hour after birth (Table 4) . Recently, 5 reports, each containing a large number of study subjects, show that the chronic infection rates in children of HBeAg-positive mothers without antiviral treatment were 2.84%
(10/352),
